Donate

industry_news_banner

Aptevo’s Ixinity, previously approved for use in people over the age of 12, just received approval for use in children under 12, per their ongoing phase 3 trial. Read the full press release here.

Facebook Comments


Sign up for E-mails, Dateline Magazine, and other ways to stay connected.